Evidence Comparison
Zenagamtide (formerly amycretin) and retatrutide are two closely watched next-generation obesity programs built around different multi-pathway strategies. This comparison separates the GLP-1/amylin dual-agonist approach from retatrutide's GLP-1/GIP/glucagon triple agonism and keeps cross-trial results in their proper context.
Metabolic & Weight Loss
Investigational
Phase 3 investigational
Unimolecular peptide agonist of GLP-1 and amylin receptors, under development in both subcutaneous and oral formulations.
Zenagamtide is one molecule targeting GLP-1 and amylin receptors, which makes it mechanistically different from the two-component CagriSema combination even though the pathway pair overlaps.
Open metabolic pipeline record →Metabolic & Weight Loss
Investigational
Phase 3 investigational
Triple GIP, GLP-1, and glucagon receptor agonist.
The strongest investigational metabolic compound on the site, but it should remain clearly separated from approved semaglutide and tirzepatide products.
Open Retatrutide guide →Save this comparison
Keep the current two- or three-compound comparison for quick access in My Tools.
Loading comparison tool...
Regulatory status and evidence level are separate ideas. A compound can have meaningful human research and still remain investigational, while an FDA-approved product can have approval only for specific indications and formulations.
BACToBasics also separates direct human intervention evidence from animal, cell, endogenous-biology, or related-molecule evidence so weaker evidence does not inherit the certainty of stronger research.
This page is generated from the same structured evidence records as the main interactive compare tool. Updating a compound's regulatory status, evidence summary, safety context, or source list updates both experiences rather than maintaining separate copies.
Read the Research & Editorial Policy →Evidence behind the comparison
These deep links are generated from the compounds in this comparison, so research and development pages stay connected as the underlying datasets grow.
Keep comparing
Compare mechanisms, evidence, regulatory status, safety context, and sources.
View comparison →
Compare mechanisms, evidence, regulatory status, safety context, and sources.
View comparison →
Compare mechanisms, evidence, regulatory status, safety context, and sources.
View comparison →
Compare mechanisms, evidence, regulatory status, safety context, and sources.
View comparison →
BACToBasics provides educational information only. Comparison pages are not medical advice, dosing advice, treatment guidance, anti-doping advice, or recommendations to use any compound.